Can a psoriasis drug tame Immunotherapy's harsh side effects?

NCT ID NCT06673329

Recruiting now Symptom relief Sponsor: Brian Henick, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injections. The goal is to see if it lowers symptom severity and the need for steroids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Brodalumab (SILIQ) injection
What this could lead to: If it works, this could offer a new way to manage painful side effects from cancer immunotherapy, potentially reducing the need for steroids.
What could go wrong: This is a very small, early-phase pilot study with only 11 participants. Brodalumab is not yet approved for this use, and it may not work or could cause new side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm breast cancer breast neoplasm colon carcinoma colonic neoplasm esophageal cancer Esophageal Neoplasms female reproductive organ cancer gastric cancer gastric neoplasm head and neck cancer Head and Neck Neoplasms kidney cancer lip and oral cavity carcinoma liver cancer Liver Neoplasms lung cancer lung neoplasm malignant pancreatic neoplasm Mouth Neoplasms neoplasm pancreatic neoplasm prostate cancer rectal cancer rectal neoplasm skin cancer skin neoplasm testicular cancer thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN TUMOR BREAST CANCER COLON CANCER ESOPHAGEAL CANCER GYNECOLOGIC CANCER HEAD AND NECK CANCER KIDNEY CANCER LIVER CANCER LUNG CANCER ORAL CANCER PANCREATIC CANCER PROSTATE CANCER RECTAL CANCER SKIN CANCER SOLID TUMOR STOMACH CANCER TESTICULAR CANCER THYROID CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.